ALKS vs BIO · P/E 14, rev $1.56B vs rev $2.58B
Alkermes Plc (ALKS) versus BIO (BIO) — a side-by-side from cached financials, not a winner call.
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
BIO (BIO) common stock.
Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
ALKS currently screens at market cap $4.78B and trailing P/E 13.8. BIO currently screens at market cap $0.
Not investment advice. Open the ALKS and BIO stock pages for the full models.
Not investment advice.